Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

Blood blood.2025028823.

https://doi.org/10.1182/blood.2025028823

Published: 2025

Includes: Supplemental data

Journal Articles

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Blood (2022) 140 (Supplement 2): LBA-3.

https://doi.org/10.1182/blood-2022-171733

Published: 2022

Journal Articles

Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group

Blood (2022) 140 (Supplement 1): 3785–3787.

https://doi.org/10.1182/blood-2022-167915

Published: 2022

Journal Articles

Six-Month Doxycycline Is Safe and Effective As Upfront Monotherapy for Stage-I Malt Lymphoma of the Ocular Adnexae: Primary Endpoint Results of the IELSG39 Trial

Blood (2022) 140 (Supplement 1): 6482–6484.

https://doi.org/10.1182/blood-2022-168712

Published: 2022

Journal Articles

Anakinra for Treatment and Prevention of CAR-T Neurotoxicity: A Systematic Review of Evidence to Inform SIE-GITMO-Sidem Guidelines

Monia Marchetti, Annalisa Chiappella, Maria Guarino, Giorgia Gobbi, Massimo Martino, Andrés J.M. Ferreri, Luca Fumagalli, Riccardo Saccardi, Mauro Montanari, Maurizio Martelli, Francesco Merli, Pier Luigi Zinzani

Blood (2022) 140 (Supplement 1): 5056–5057.

https://doi.org/10.1182/blood-2022-165125

Published: 2022

Journal Articles

Ibrutinib Alone or in Combination with R-CHOP Chemoimmunotherapy in Relapsed or Refractory Primary Central Nervous System Lymphoma (rrPCNSL): A «Real-Life» Study

Blood (2022) 140 (Supplement 1): 6678–6680.

https://doi.org/10.1182/blood-2022-170143

Published: 2022

Journal Articles

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients

Matthew R. Wilson, Toby A. Eyre, Amy A. Kirkwood, Nicole Wong Doo, Carole Soussain, Sylvain Choquet, Nicolás Martinez-Calle, Gavin Preston, Matthew Ahearne, Elisabeth Schorb, Marie-Pierre Moles-Moreau, Matthew Ku, Chiara Rusconi, Jahanzaib Khwaja, Mayur Narkhede, Katharine L. Lewis, Teresa Calimeri, Eric Durot, Loïc Renaud, Andreas Kiesbye Øvlisen, Graham McIlroy, Timothy J. Ebsworth, Johnathan Elliot, Anna Santarsieri, Laure Ricard, Nimish Shah, Qin Liu, Adam S. Zayac, Francesco Vassallo, Laure Lebras, Louise Roulin, Naelle Lombion, Kate Manos, Ruben Fernandez, Nada Hamad, Alberto Lopez-Garcia, Deirdre O'Mahony, Praveen Gounder, Nathalie Forgeard, Charlotte Lees, Kossi Agbetiafa, Tim Strüßmann, Thura Win Htut, Aline Clavert, Hamish Scott, Anna Guidetti, Brett R. Barlow, Emmanuelle Tchernonog, Jeffery Smith, Fiona Miall, Christopher P. Fox, Chan Y. Cheah, Tarec Christoffer El Galaly, Andrés J.M. Ferreri, Kate Cwynarski, Pamela McKay

Blood (2022) 139 (16): 2499–2511.

https://doi.org/10.1182/blood.2021014506

Published: 2022

Includes: Supplemental data

Journal Articles

Lenalidomide Maintenance Significantly Improves Survival Figures in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Final Results of a Multicentre Phase II Trial

Blood (2016) 128 (22): 474.

https://doi.org/10.1182/blood.V128.22.474.474

Published: 2016

Journal Articles

Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial

Andrés J.M. Ferreri, MD, Kate Cwynarski, MBBS, FRPATH, PhD, Elisa Jacobsen Pulczynski, MD, Christopher P. Fox, MBChB, PhD, Elisabeth Schorb, MD, Paul La Rosée, MD, Mascha Binder, MD, Alberto Fabbri, MD, Valter Torri, MD, Eleonora Minacapelli, MD, Monica Falautano, MD, Fiorella Ilariucci, MD, Achille Ambrosetti, MD, Alexander Röth, MD, Claire Jane Hemmaway, MD, Peter M Johnson, MA, MD, Kim Linton, MBChB, MRCP, PhD, Tobias Pukrop, MD, Jette Sonderskov Gorlov, MD, Monica Balzarotti, MD, Georg Hess, MD, Ulrich Keller, MD, Stephan Stilgenbauer, MD, Jens P. Panse, MD, Alessandra Tucci, MD, Lorella Orsucci, MD, Francesco Pisani, MD, Alessandro Levis, MD, Stefan W. Krause, MD, Hans-Joachim Schmoll, MD PhD, Bernd Hertenstein, MD, Mathias Rummel, MD PhD, Jeffery Smith, MD, Michael Pfreundschuh, MD, PhD, Giuseppina Cabras, MD, Francesco Angrilli, MD, Maurilio Ponzoni, MD, Martina Deckert, MD, Letterio S. Politi, MD, Jurgen Finke, MD, Michele Reni, MD, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus, MD

Blood (2016) 128 (22): 511.

https://doi.org/10.1182/blood.V128.22.511.511

Published: 2016

Journal Articles

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Blood (2016) 128 (22): 1099.

https://doi.org/10.1182/blood.V128.22.1099.1099

Published: 2016

Journal Articles

Clinical Activity and Safety of RP6530, a Dual PI3Kδ/γ Inhibitor, in Patients with Advanced Hematologic Malignancies: Final Analysis of a Phase 1 Multicenter Study

Carmelo Carlo-Stella, MD, Richard Delarue, MD, Prajak J Barde, MD, Lydia Scarfo, Uday Kumar, Srikant Viswanadha, PhD, Silvia Laura Locatelli, PhD, Sara Gandolfi, MD, Valeria Pittari, MD, Lucia Morello, Massimo Magagnoli, Armando Santoro, Andrés J.M. Ferreri, MD

Blood (2016) 128 (22): 3011.

https://doi.org/10.1182/blood.V128.22.3011.3011

Published: 2016

Journal Articles

A Molecular Model for the Prediction of Progression Free Survival in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation: Results from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL)

Davide Rossi, MD PhD, Simone Ferrero, Alessio Bruscaggin, Paola Ghione, Alice Di Rocco, Valeria Spina, Vittorio Stefoni, Giovannino Ciccone, Daniela Barbero, Luigia Monitillo, Maria Gomes Da Silva, Armando Santoro, MD, Annalia Molinari, Andres J.M. Ferreri, Sergio Cortelazzo, Marco Ladetto, Gianluca Gaidano

Blood (2015) 126 (23): 336.

https://doi.org/10.1182/blood.V126.23.336.336

Published: 2015

Journal Articles

Lenalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) in Patients with Chemosensitive Relapse of Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT) or Experienced Relapse after Transplantation: Results of a Multicentre Phase II Trial

Andrés J.M. Ferreri, Marianna Sassone, Marianna Chiozzotto, Michele Spina, MD, Alessandra Tucci, Alice Di Rocco, Alberto Fabbri, Caterina Stelitano, Maurizio Frezzato, Renato Zambello, Giovanni Bertoldero, Chiara Rusconi, MD, Annalisa Arcari, Lydia Scarfo, Silvia Govi, Maurilio Ponzoni, MD, Francesco Zaja, MD

Blood (2015) 126 (23): 1547.

https://doi.org/10.1182/blood.V126.23.1547.1547

Published: 2015

Journal Articles

The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL)

Blood (2015) 126 (23): 2735.

https://doi.org/10.1182/blood.V126.23.2735.2735

Published: 2015

Journal Articles

A Dose Escalation Study of RP6530, a Novel Dual PI3K Delta/Gamma Inhibitor, in Patients with Relapsed/Refractory Hematologic Malignancies

Carmelo Carlo-Stella, MD, Richard Delarue, MD, Prajak J Barde, MD, Lydia Scarfo, Thamila Saheb, Uday Kumar, Srikant Viswanadha, PhD, Sara Gandolfi, MD, Valeria Pittari, MD, Armando Santoro, MD, Silvia Laura Locatelli, PhD, Swaroop Vakkalanka, PhD, Paolo Ghia, MD PhD, Andres J.M. Ferreri

Blood (2015) 126 (23): 1495.

https://doi.org/10.1182/blood.V126.23.1495.1495

Published: 2015

Journal Articles

High Doses of Antimetabolites Followed By High-Dose Sequential Chemoimmunotherapy and Autologous Stem Cell Transplant in Patients with Systemic B-Cell Lymphoma and Secondary Central Nervous System Involvement: Final Results of a Multicenter Phase II Trial

Andrés J.M. Ferreri, Giovanni Donadoni, MD, Maria Giuseppina Cabras, MD, Caterina Patti, MD, Michael Mian, Renato Zambello, MD, Corrado Tarella, MD, Massimo Di Nicola, MD, Alfonso D'Arco, Gianluca Doa, Marta Bruno-Ventre, Marco Foppoli, MD, Alessandro Fanni, MD, Antonino Mulè, MD, Fabio Ciceri, MD, Federico Caligaris-Cappio, MD

Blood (2014) 124 (21): 1724.

https://doi.org/10.1182/blood.V124.21.1724.1724

Published: 2014

Journal Articles

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma

Jacopo Mariotti, MD, Anna Guidetti, MD, Michele Magni, MD, Paola Matteucci, MD, Liliana Devizzi, MD, Andrés J.M. Ferreri, Paolo Corradini, MD, Anna Dodero, MD, Amalia De Renzo, Alessandro Massimo Gianni, MD, Massimo Di Nicola, MD

Blood (2014) 124 (21): 1734.

https://doi.org/10.1182/blood.V124.21.1734.1734

Published: 2014

Journal Articles

NF-κB Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program

Blood (2014) 124 (21): 1620.

https://doi.org/10.1182/blood.V124.21.1620.1620

Published: 2014

Journal Articles

Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program

Blood (2014) 124 (21): 143.

https://doi.org/10.1182/blood.V124.21.143.143

Published: 2014

Journal Articles

Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10

Blood (2014) 124 (21): 799.

https://doi.org/10.1182/blood.V124.21.799.799

Published: 2014

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group

Six-Month Doxycycline Is Safe and Effective As Upfront Monotherapy for Stage-I Malt Lymphoma of the Ocular Adnexae: Primary Endpoint Results of the IELSG39 Trial

Anakinra for Treatment and Prevention of CAR-T Neurotoxicity: A Systematic Review of Evidence to Inform SIE-GITMO-Sidem Guidelines

Ibrutinib Alone or in Combination with R-CHOP Chemoimmunotherapy in Relapsed or Refractory Primary Central Nervous System Lymphoma (rrPCNSL): A «Real-Life» Study

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients

Lenalidomide Maintenance Significantly Improves Survival Figures in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Final Results of a Multicentre Phase II Trial

Rituximab Plus Lenalidomide Versus Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. First Analysis of Survival Endpoints of the Randomized Phase-2 Trial SAKK 35/10

Clinical Activity and Safety of RP6530, a Dual PI3Kδ/γ Inhibitor, in Patients with Advanced Hematologic Malignancies: Final Analysis of a Phase 1 Multicenter Study

A Molecular Model for the Prediction of Progression Free Survival in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation: Results from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL)

The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL)

A Dose Escalation Study of RP6530, a Novel Dual PI3K Delta/Gamma Inhibitor, in Patients with Relapsed/Refractory Hematologic Malignancies

High Doses of Antimetabolites Followed By High-Dose Sequential Chemoimmunotherapy and Autologous Stem Cell Transplant in Patients with Systemic B-Cell Lymphoma and Secondary Central Nervous System Involvement: Final Results of a Multicenter Phase II Trial

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma

NF-κB Subunit c-Rel Cooperates with Myc and Mutated p53 to Confer Significantly Worse Survival in Patients with Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program

Akt Activation Confers an Inferior Survival in Patients with Activated B-Cell Subtype of Diffuse Large B-Cell Lymphoma: A Report from the International DLBCL Rituximab-CHOP Consortium Program

Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only